KDR and hepatocellular carcinoma: Therefore, this study provided the first and strong—evidence of the benefit provided by combining an ICI and a VEGFR inhibitor for patients with advanced HCC, and its superiority over sorafenib has undoubtedly already changed the standard of care for these patients, where it has substituted sorafenib as first-line treatment in most cases.